HRP20150765T1 - Amid derivati piperidin- i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za lijeäśenje tjeskobe, boli i drugih stanja - Google Patents

Amid derivati piperidin- i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za lijeäśenje tjeskobe, boli i drugih stanja Download PDF

Info

Publication number
HRP20150765T1
HRP20150765T1 HRP20150765TT HRP20150765T HRP20150765T1 HR P20150765 T1 HRP20150765 T1 HR P20150765T1 HR P20150765T T HRP20150765T T HR P20150765TT HR P20150765 T HRP20150765 T HR P20150765T HR P20150765 T1 HRP20150765 T1 HR P20150765T1
Authority
HR
Croatia
Prior art keywords
4alkyl
group
substituted
carboxylic acid
ylamide
Prior art date
Application number
HRP20150765TT
Other languages
English (en)
Inventor
Richard Apodaca
J. Guy Breitenbucher
Kanaka Pattabiraman
Mark Seierstad
Wei Xiao
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20150765T1 publication Critical patent/HRP20150765T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Claims (34)

1. Spoj Formule (I) [image] gdje: Z je -N- ili >CH; R1 je -H ili -C1-4alkil; Ar1 je 2-tiazolil, 2-piridil, 3-piridil, 4-piridil, 2-pirimidinil, 4-pirimidinil, 5-pirimidinil, svaki nesupstituiran ili supstituiran na članku prstena ugljika sa jednom ili dvije Ra funkcionalne grupe;gdje je svaka Ra funkcionalna grupa nezavisno izabrana iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc svaki nezavisno -H ili -C1-4alkil; i Ar2 je: (a) nesupstituirani 1-naftil; ili fenantrenil, pirenil, fluorenil, 2-naftil, ili N-Rd-9H-karbazolil funkcionalna grupa, gde je Rd izabran iz grupe koja se sastoji od -H, -C1-4alkila, i fenila, svake navedene funkcionalne grupe nesupstituirane ili supstituirane sa jednim, dva, ili tri Re supstituenta, gdje je svaki Re supstituent nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkil, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (b) fenil fuzioniran na dva susjedna atoma prstena ugljika za grupu izabranu iz grupe koja se sastoji od -(CH2)3-5- koja ima 0 ili 1 duplu vezu, -OCH2CH2O-, i -OCF2O-čime formira fuzioniranu prstenastu strukturu; ili fenil supstituiran na susjednim atomima ugljikovog prstena sa -OCH2O- čime formira 4-benzo[1,3]dioksolil; svaka fenil funkcionalna grupa dalje nesupstituirana ili supstituirana sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (c) Ar6, gdje je Ar6 šestočlani monociklički heteroaril koji ima ugljik kao točku vezanja, sa jednim ili dva dušikova heteroatoma, nesupstituirana ili supstituirana sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (d) devetočlani ili desetočlani fuzionirani biciklični heteroaril koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa atomom ugljika kao točkom vezivanja prstena, i opcijski ima do četiri dodatna atoma ugljikova prstena, zamijenjena sa dušikom, spomenuti fuzionirani biciklični heteroaril koji nema više od pet heteroatoma, i nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (e) fenil supstituiran na trećoj i četvrtoj poziciji sa Rg, i opcijski dalje supstituiran sa jednim, dva, ili tri supstituenta Rh, gdje je svako Rg nezavisno izabrano iz grupe koja se sastoji od -C2-8alkila, -C2-8alkenila, -OC3-8cikloalkila, -OC3-8heterocikloalkila, i -O-C2-10alkila opcijski supstituiran sa -NRiRj, gdje su Ri i Rj svako nezavisno –H ili -C1-8alkil, ili Ri i Rj uzeti zajedno sa atomom prstena dušika od veze čime formiraju petočlani, šestočlani, ili sedmočlani heterocikloalkil prsten opcijski imajući jedan dodatni atom prstena ugljika zamijenjen sa O, S, >NH, ili >NC1-4alkilom; i svaki Rh supstituent je nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -C02C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno opisano; (f) fenil supstituiran na trećoj ili četvrtoj poziciji sa -1-Ar3, gdje je: • L je veznik izabran iz grupe koja se sastoji od -(CH2)1-3-, -CH=CH-, -O-, -OCH2-, -CH2O-, -NH-, >NC1-4alkil, >S(=O)0-2, -OSO2-, -C≡C-, -C(=O)-, i kovalentne veze; i • o Ar3 je funkcionalna grupa izabrana iz grupe koja se sastoji od: (1) fenila, naftila, i fenantrenila, (2) Ar6’, gdje je Ar6’ šestočlani monociklički heteroaril koji ima ugljik kao točku spajanja, koji ima jedan ili dva heteroatoma dušika, (3) Ar5’, gdje je Ar5’ petočlani monociklički heteroaril koji ima ugljik kao točku spajanja, sa jednim heteroatomom izabranim iz grupe koja se sastoji od: O, S, >NH, i >NRf, gdje je Rf -C1-8alkil ili -C0-3fenalkil, i ima nula, jedan, dva, ili tri dodatna heteroatoma dušika, i (4) devetočlani ili desetočlani fuzionisani biciklični heteroaril, koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa ugljikom kao točkom vezivanja prstena, i koji opcijski ima do četiri dodatna atoma ugljikovog prstena zamijenjena sa dušikom, spomenutim fuzioniranim bicikličnim heteroarilom koji nema više od 5 heteroatoma; gdje je svaka od funkcionalnih grupa (1) do (4) opcijski de-supstituirana na susjednim ugljicima sa -OC1-4alkilenO-, -(CH2)2-3NH-, -(CH2)1-2NH(CH2)-, -(CH2)2-3N(C1-4alkil)-, ili -(CH2)1-2N(C1-4alkil)(CH2)- čime formira fuzioniranu prstenastu strukturu, i opcijski dalje supstituirana sa jednim, dva, ili tri supstituenta Rk, gdje je svaki Rk supstituent nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkil, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkil, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (g) 2-hidroksifenil ili 2-metoksifenil, nesupstituirani ili supstituirani sa jednim, dva, ili tri supstituenta Rl, gdje je svaki Rl supstituent nezavisno izabran iz grupe koja se sastoji od -CH3, 6-C2-4alkila, 6- C2-4alkenil, -OH, -OCH3, 6-OC2-6alkila, halo, -CF3, -OCF3, -SCF3, -SH, -SC1-4alkila, -SOC1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (h) 4-halofenil, nesupstituiran ili supstituiran sa jednim, dva, ili tri supstituenta Rm, gdje je svaki Rm supstituent nezavisno izabran iz grupe koja se sastoji od -CH3, 2-C2-4alkila, 2-C2-4alkenila, 3-hidroksi, 4-hidroksi, -OCH3, 2-OC2-6alkil, halo, -CF3, -OCF3, -SCF3, -SH, -SC1-4alkila, -SO2C1-4alkila, -CO2C1-4alkila,- CO2H, -COC1-4alkil, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; ili (i) 2-bromofenil, 3-metilfenil, 3-metoksifenil, 4-metoksifenil, ili 3,4-d imetoksifenil; ili farmaceutsko prihvatljive soli takvog spoja.
2. Spoj kao što je definirano prema patentnom zahtjevu 1, naznačen time da R1 je metil.
3. Spoj kao što je definirano prema patentnom zahtjevu 1, naznačen time da Ar1 je 2-tiazolil.
4. Spoj kao što je definirano prema patentnom zahtjevu 1, naznačen time da Ar2 je 2-metoksifenil, nesupstituiran ili supstituiran sa jednim, dva, ili tri supstituenta R|.
5. Spoj kao što je definirano prema patentnom zahtjevu 1, naznačen time da Ar2 je 3,4-dihlorofenil.
6. Spoj kao što je definirano prema patentnom zahtjevu 1, naznačen time da: Z je -N- ili >CH; R1 je -H ili -C1-4alkil; Ar1 je 2-piridil, 3-piridil, 4-piridil, 2-pirimidinil, 4-pirimidinil, 5-pirimidinil, svaki nesupstituiran ili supstituiran na članu ugljik prstena sa jednom ili dvije Ra funkcionalne grupe; gdje je svaka Ra funkcionalna grupa nezavisno izabrana iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc svaki nezavisno -H ili -C1-4alkil; i Ar2 je: (a) nesupstituiran 1-naftil; ili fenantrenil, pirenil, fluorenil, 2-naftil, ili N-Rd-9H-karbazolil funkcionalne grupe, gdje je Rd izabrano iz grupe koja se sastoji od -H, -C1-4alkila, i fenila, svaka spomenuta funkcionalna grupa nesupstituirana ili supstituirana sa jednim, dva, ili tri Re supstituenta, gdje je svaki Re supstituent nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkil, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (b) fenil fuzioniran na dva susjedna atoma ugljikovog prstena za grupu izabranu iz grupe koja se sastoji od -(CH2)3-5- koji ima 0 ili 1 duple veze, -OCH2CH2O-, i -OCF2O- čime formira fuzioniranu prstenastu strukturu; ili fenil supstituiran na susjedne atome ugljikovog prstena sa -OCH2O- čime formira 4-benzo[1,3]dioksolil; svaka fenil funkcionalna grupa dalje nesupstituirana ili supstituirana sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (c) Ar6, gdje Ar6 je šestočlani monociklički heteroaril koji ima ugljik kao točku vezivanja, sa jednim ili dva heteroatoma dušika, nesupstituirana ili supstituirana sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (d) devetočlani ili desetočlani fuzionirani biciklični heteroaril koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa atomom ugljika kao točkom vezanja prstena, i koji opcijski ima do četiri dodatna atoma ugljikovog prstena zamijenjena sa dušikom, spomenuti fuzionirani biciklični heteroaril koji nema više od pet heteroatoma, i nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (e) fenil supstituiran na trećoj i četvrtoj poziciji sa Rg, i opcijski dalje supstituiran sa jednim, dva, ili tri Rh supstituenta, gdje je svako Rg nezavisno izabrano iz grupe koja se sastoji od -C2-8alkila, -C2-8alkenila, -OC3-8cikloalkila, -OC3-8heterocikloalkila, i -O-C2-10alkila opcijski supstituirano sa -NRiRj, gdje su Ri i Rj svako nezavisno -H ili -C1-8alkil, ili Ri i Rj su uzeti zajedno sa atomom vezujućeg dušikovog prstena čime formiraju petočlani, šestočlani, ili sedmočlani heterocikloalkil prsten koji opcijski ima jedan dodatni atom ugljik prstena zamijenjen sa O, S, >NH, ili >NC1-4alkil; i svaki Rh supstituent je nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkil, -CO2C1-4alkila, -CO2H, -COC1-4alkil, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (f) fenil supstituiran na trećoj ili četvrtoj poziciji sa -1-Ar3, gdje: • L je veznik izabran iz grupe koja se sastoji od -(CH2)1-3-, -CH=CH-, -O-, -OCH2-, -CH2O-, -NH-, >NC1-4alkil, >S(=O)0-2, -OSO2-, -C≡C-, -C(=O)-, i kovalentne veze; i • o Ar3 je funkcionalna grupa izabrana iz grupe koja se sastoji od: (1) fenil, naftil, i fenantrenil, (2) Ar6’, gdje je Ar6’ šestočlani monociklički heteroaril koji ima uglik kao točku vezanja, koji ima jedan ili dva heteroatoma dušika, (3) Ar5’, gdje je Ar5’ petočlani monociklički heteroaril koji ima ugljik kao tačku vezivanja, sa jednim heteroatomom izabranim iz grupe koja se sastoji od O, S, >NH, i >NRf, gde Rf je -C1-8alkil ili -C0-3fenalkil, i koji ima nula, jedan, dva, ili tri dodatna heteroatoma dušika, i (4) devetočlani ili desetočlani fuzionirani biciklični heteroaril, koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa ugljikom kao točkom vezanja, i koji opcijski ima do četiri dodatna atoma ugljikovog prstena zamijenjena sa dušikom, spomenutim fuzioniran biciklični heteroaril koji nema više od pet heteroatoma; gdje svaka od funkcionalnih grupa (1) do (4) je opcijski de-supstituirana na susjednim ugljicima sa -OC1-4alkilenomO-, -(CH2)2-3NH-, -(CH2)1-2NH(CH2)-, -(CH2)2-3N(C1-4alkil)-, ili -(CH2)1-2N(C1-4alkil)(CH2)- čime formira fuzioniranu prsten strukturu, i opcijski je dalje supstituiran sa jednim, dva, ili tri Rk supstituenta, gdje je svaki Rk supstituent nezavisno izabran iz grupe koja se sastoji od -C1-4alkil, -C2-4alkenil, -OH, -OC1-4alkil, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkil, -OSO2C1-4alkil, -CO2C1-4alkil, -CO2H, -COC1-4alkil, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (g) 2-hidroksifenil, nesupstituiran ili supstituiran sa jednim, dva, ili tri RI supstituenta, gdje je svaki RI supstituent nezavisno izabran iz grupe koja se sastoji od -CH3, 6-C2-4alkila, 6-C2-4alkenila, -OH, -OCH0, 6-OC2-6alkila, halo, -CF3, -OCF3, -SCF3, -SH, -SC1-4alkila, -SO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (h) 4-halofenil, nesupstituiran ili supstituiran sa jednim, dva, ili tri Rm supstituenta, gdje je svaki Rm supstituent nezavisno izabran iz grupe koja se sastoji od -CH3, 2-C2-4alkila, 2-C2-4alkenila, 3-hidroksi, 4-hidroksi, -OCH3, 2-OC2-6alkila, halo, -CF3, -OCF3, -SCF3, -SH, -SC1-4alkila, -SO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; ili (i) 2-bromofenil, 3-metilfenil, 3-metoksifenil, 4-metoksifenil, ili 3,4-dimetoksifenil; ili farmaceutsko prihvatljive soli takvog spoja.
7. Spoj kao što je definirano prema patentnom zahtjevu 6, naznačen time da Z je -N-.
8. Spoj kao što je definirao prema patentnom zahtjevu 7, naznačen time da R1 je -H.
9. Spoj kao što je definirano prema patentnom zahtjevu 7, naznačen time da Ar2 je fenantren-9-il, piren-1-il, 9H-fluoren-2-il, 1-naftil, 2-naftil, 1-hidroksinaftalen-2-il, 6-metoksinaftalen-2-il, ili 9-etil-9H-karbazol-3-il, svaki nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano.
10. Spoj kao što je definirano prema patentnom zahtjevu 7, naznačen time da Ar2 je indanil, indenil, tetrahidronaftil, 2,3-dihidro-benzofuranil, hromanil, 2,3-dihidro-benzo[1,4]dioksinil, ili 2,2-difluoro-benzo[1,3]dioksolil, svaki nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano.
11. Spoj kao što je definirano prema patentnom zahtjevu 7, naznačen time da Ar2 je fenil-1 H-pirolil, 2-piridil, 3-piridil, 4-piridil, ili 6-bromopiridin-2-il, svaki nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano.
12. Spoj kao što je definirano prema patentnom zahtjevu 7, naznačen time da Ar2 je fenil supstituiran na trećoj ili četvrtoj poziciji sa -1-Ar3, gdje L je -CH=CH-, -O-, -OCH2-, -SO2-, -OSO2-, ili kovalentna veza.
13. Spoj kao što je definirano prema patentnom zahtjevu 7, naznačen time da Ar2 je 2-hidroksifenil, 5-bromo-2-hidroksi-3-metoksifenil, ili 5-brom-2-hidroksifenil.
14. Spoj kao što je definirano prema patentnom zahtjevu 8, naznačen time da Ar1 je 2-piridil, 3-piridil, 4-piridil, 2-pirimidinil, ili 4-pirimidinil, svaki nesupstituiran ili supstituiran na atomu ugljikovog prstena sa jednom ili dvije Ra funkcionalne grupe kao što je prethodno definirano.
15. Spoj kao što je definirano prema patentnom zahtjevu 8, naznačen time da Ar2 je nesupstituirani 2,2-difluoro-benzo[1,3]dioksolil.
16. Spoj kao što je definirano prema patentnom zahtjevu 8, naznačen time da Ar2 je nesupstituirani 4-benzo[1,3]dioksolil.
17. Spoj kao što je definirano prema patentnom zahtjevu 8, naznačen time da Ar2 je 2-indolil, 3-indolil, 2-hinolinil, 3-hinolinil, ili 2-hinoksalinil, svaki nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano.
18. Spoj kao što je definirano prema patentnom zahtjevu 8, naznačen time da Ar2 je 2-hinolinil ili 3-hinolinil.
19. Spoj kao što je definirano prema patentnom zahtjevu 8, naznačen time da Ar2 je 4-etilfenil, 4-izopropilfenil, 3-vinilfenil, 3-etoksifenil, 4-etoksifenil, 3-propoksifenil, 4-propoksifenil, 3-izobutoksifenil, 4-izopropoksifenil, 3-izobutoksifenil, 4-izobutoksifenil, 4-cikloheksiloksifenil, 3-(2-dimetilaminoetoksi)fenil, 3-(2-piperidin-1-iletoksi)fenil, 3-(3-dimetilaminopropoksi)fenil, ili 3-(3-piperidin-1-ilpropoksi)fenil.
20. Spoj kao što je definirano prema patentnom zahtjevu 8, naznačen time da Ar3 je 4-hlorofenil, 3,4-dihlorofenil, 4-metilfenil, 4-t-butilfenil, 3-trifluorometilfenil, 4-metoksifenil, 3,5-dihlorofenil, 1-naftil, 2-naftil, 3-hlorofenil, 9-fenantrenil, 4-karbometoksilfenil, 4-metansulfonilfenil, 3-metoksifenil, benzo[1,3]dioksol-5-il, ili nesupstituirani fenil.
21. Spoj kao što je definirano prema patentnom zahtjevu 8, naznačen time da Ar2 je 3,4-dibromofenil, 3-bromo-4-fluorofenil, ili 4-hloro-3-trifluorometil.
22. Spoj kao što je definirano prema patentnom zahtjevu 8, naznačen time da Ar2 je 3,4-dibromofenil.
23. Spoj kao što je definirano prema patentnom zahtjevu 1 naznačen time da je izabran iz grupe koja se sastoji od: 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina piridin-3-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina piridin-2-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina piridin-4-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina pirimidin-2-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1- karboksilna kiselina piridin-3-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1- karboksilna kiselina piridin-4-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1- karboksilna kiselina pirimidin-2-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1- karboksilna kiselina piridin-2-ilamida; 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1- karboksilna kiselina piridin-3-ilamida; 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1- karboksilna kiselina piridin-4-ilamida; 4-hinolin-3-ilmetil-piperazin-1- karboksilna kiselina pirimidin-4-ilamida; 4-(2,2-difluoro-benzo[1 ,3]dioksol-5-ilmetil)-piperazin-1- karboksilna kiselina pirimidin-4-ilamida; 4-(3,4-dibromo-benzil)-piperazin-1- karboksilna kiselina pirimidin-4-ilamida; i farmaceutski prihvatljivih soli istih.
24. Spoj kao što je definirano prema patentnom zahtjevu 1 naznačen time da je izabran iz grupe koja se sastoji od: 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina tiazol-2-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1-karboksilna kiselina tiazol-2-ilamida; i farmaceutski prihvatljivih soli istih.
25. Spoj Formule (I): [image] gdje: Z je -N- ili >CH; R1 je -H ili -C1-4alkil; Ar1 je 2-tiazolil, 2-piridil, 3-piridil, 4-piridil, 2-pirimidinil, 4-pirimidinil, 5-pirimidinIl, svaki nesupstituiran ili supstituiran na članu ugljikovog prstena sa jednom ili dvije Ra funkcionalne grupe; gdje je svaka Ra funkcionalna grupa nezavisno izabrana iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc oba nezavisno -H ili -C1-4alkil; i Ar2 je: (a) fenantrenil, pirenil, fluorenil, naftil, ili N-Rd-9H-karbazolil funkcionalne grupe, gdje Rd je izabrano iz grupe koja se sastoji od -H, -C1-4alkil, i fenil, svaka spomenuta funkcionalna grupa nesupstituirana ili supstituirana sa jednim, dva, ili tri Re supstituenta, gdje je svaki Re supstituent nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4 alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (b) fenil fuzioniran na dva susjedna atoma ugljikovog prstena za grupu izabranu iz grupe koja se sastoji od -(CH2)3-5-koja ima 0 ili 1 duple veze, OCH2CH2O-, -OCF2O- i -OCH2O- čime formira fuzioniranu prstenastu strukturu, nesupstituiranu ili supstituiranu sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (c) Ar6, gdje Ar6 je šestočlani monociklički heteroaril koji ima ugljik kao točku vezanja, sa jednim ili dva heteroatoma dušika, nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (d) devetočlani ili desetočlani fuzionirani biciklični heteroaril koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa atomom ugljika kao točkom prstenastog vezanja, i koji opcijski ima do četiri dodatna atoma ugljikovog prstena zamijenjena sa dušikom, spomenutim fuzioniranim bicikličnim heteroarilom koji ima ne više od pet heteroatoma, i nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (e) fenil supstituiran na trećoj i četvrtoj poziciji sa Rg, i opcijski dalje supstituiran sa jednim, dva, ili tri supstituenta Rh, gdje je svaki Rg nezavisno izabran iz grupe koja se sastoji od -C2-8alkila, -C2-8alkenila, -OC3-8cikloalkila, -OC3-8heterocikloalkila, i -O-C2-10alkila opcijski supstituiran sa -NRiRj, gdje su Ri i Rj oba nezavisno -H ili -C1-8alkil, ili Ri i Rj su uzeti zajedno sa vezujućim atomom dušikovog prstena čime formiraju petočlani, šestočlani, ili sedmočlani heterocikloalkil prsten koji opcijski ima jedan dodatni atom ugljikovog prstena zamijenjen sa O, S, >NH, ili >NC1-4alkil; i svaki Rh supstituent je nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (f) fenil supstituiran na trećoj ili četvrtoj poziciji sa -1-Ar3, gdje: • L je veznik izabran iz grupe koja se sastoji od -(CH2)1-3-, -CH=CH-, -O-, -OCH2-, -CH2O-, -NH-, >NC1-4alkil, >S(=O)0-2, -OSO2-, -CΞC-, -C(=O)-, i kovalentne veze; i • Ar3 je funkcionalna grupa izabrana iz grupe koja se sastoji od: (1) fenil, naftil, i fenantrenil, (2) Ar6’, gdje Ar6’ je šestočlani monociklički heteroaril koji ima ugljik kao točku vezivanja, koji ima jedan ili dva heteroatoma dušika, (3) Ar5’, gdje Ar5’ je petočlani monociklički heteroaril koji ima ugljik kao točku vezivanja, sa jednim heteroatomom izabranim iz grupe koja se sastoji od O, S, >NH, i >NRf, gde Rf je -C1-8alkila ili -C0-3fenalkila, i koji ima nula, jedan, dva, ili tri dodatna heteroatoma dušika, i (4) devetočlani ili desetočlani fuzionirani biciklični heteroaril, koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa ugljikom kao točkom prstenastog vezanja, i koji opcijski ima do četiri dodatna atoma ugljikovog prstena zamijenjena sa dušikom, spomenutim fuzioniranim bicikličnim heteroarilom koji ima ne više od pet heteroatoma; gdje svaka od funkcionalnih grupa (1) do (4) je opcijski de-supstituirana na susjednim ugljicima sa -OC1-4alkilenO-, -(CH2)2-3NH-, -(CH2)1-2NH(CH2)-, -(CH2)2-3N(C1-4alkil)-, ili -(CH2)1-2N(C1-4alkil)(CH2)- čime formira fuzioniranu prstenastu strukturu, i opcijski je dalje supstituiran sa jednim, dva, ili tri supstituenta Rk, gdje je svaki Rk supstituent nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkil, -OSO2C1-4alkil, -CO2C1-4alkil, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (g) 2-hidroksifenil ili 2-metoksifenil, nesupstituiran ili supstituiran sa jednim, dva, ili tri supstituenta RI, gdje je svaki RI supstituent nezavisno izabran iz grupe koja se sastoji od -CH3, 6-C2-4alkila, 6- C2-4alkenila, -OH, -OCH3, 6-OC2-6alkila, halo, -CF3, -OCF3, -SCF3, -SH, -SC1-4alkila, -SO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (h) 4-halofenil, nesupstituiran ili supstituiran sa jednim, dva, ili tri supstituenta Rm, gdje je svaki Rm supstituent nezavisno izabran iz grupe koja se sastoji od -CH3, 2-C2-4alkila, 2-C2-4alkenila, 3-hidroksi, 4-hidroksi, -OCH3, 2-OC2-6alkila, halo, -CF3, -OCF3, -SCF3, -SH, -SC1-4alkila, -SO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; ili (i) 2-bromofenil, 3-metilfenil, 3-metoksifenil, 4-metoksifenil, ili 3,4-dimetoksifenil; ili farmaceutski prihvatljive soli takvog spoja za primjenu u liječenju bolesti, poremećaja ili medicinskih stanja posredovanih FAAH aktivnošću.
26. Spoj prema patentnom zahtjevu 25, naznačen time da je spomenuti spoj izabran iz grupe koja se sastoji od: 4-(3,4-dibromo-benzil)-piperazin-1-karboksilna kiselina piridin-4-ilamida; 4-(3,4-dibromo-benzil)-piperazin-1-karboksilna kiselina piridin-2-ilamida; 4-(3,4-dibromo-benzil)-piperazin-1-karboksilna kiselina piridin-3-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina piridin-3-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina piridin-2-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina piridin-4-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina pirimidin-2-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1-karboksilna kiselina piridin-3-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1-karboksilna kiselina piridin-4-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1-karboksilna kiselina pirimidin-2-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazine-1-karboksilna kiselina piridin-2-ilamida; 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1-karboksilna kiselina piridin-3-ilamida; 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazine-1-karboksilna kiselina piridin-4-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina pirimidin-4-ilamida; 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1-karboksilna kiselina pirimidin-4-ilamida; 4-(3,4-dibromo-benzil)-piperazin-1-karboksilna kiselina pirimidin-4-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina tiazol-2-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1-karboksilna kiselina tiazol-2-ilamida; i farmaceutsko prihvatljive soli istih.
27. Spoj prema patentnom zahtjevu 25, naznačen time da su bolest, poremećaj, ili medicinsko stanje izabrano iz grupe koja se sastoji od: anksioznost, bol, poremećaji spavanja, poremećaji ishrane, inflamacija, poremećaji kretanja, sindrom HIV propadanja, povreda glave, šlog, Alzheimerova bolest, epilepsija, Touretteov sindrom, Niemann-Pikova bolest, Parkinsonova bolest, Huntingtonova horea, optički neuritis, autoimuni uveitis, apstinentska kriza, mučnina, povraćanje, seksualna disfunkcija, post traumatski stresni poremećaj, cerebralni vazospazam, glaukom, sindrom nadraženih crijeva, inflamatorna bolest crijeva, imunosupresija, gastroezofagusna refluksna bolest, paralitički ileus, sekretorna dijareja, čir na želucu, reumatoidni artritis, neželjena trudnoća, hipertenzija, karcinom, hepatitis, alergijska bolest disajnih puteva, autoimuni dijabetes, intraktabilni pruritis, i neuroinflamacija.
28. Spoj prema patentnom zahtjevu 25, naznačen time da su bolest, poremećaj, ili medicinsko stanje izabrani iz grupe koja se sastoji od: anksioznost, bol, inflamacija, poremećaji spavanja, poremećaji ishrane, i poremećaji kretanja.
29. Spoj prema patentnom zahtjevu 25, naznačen time da su bolest, poremećaj, ili medicinsko stanje multipla skleroza.
30. Spoj prema patentnom zahtjevu 25, naznačen time da su bolest, poremećaj ili medicinsko stanje bol kod inflamacije.
31. Farmaceutski pripravak pri liječenju bolesti, poremećaja, ili medicinskog stanja posredovanog FAAH aktivnošću, naznačen time da sadrži: (a) efektivnu količinu agensa izabranog iz grupe koja se sastoji od spoja Formule (I): [image] gdje: Z je -N- ili >CH; R1 je -H ili -C1-4alkil; Ar1 je 2-tiazolil, 2-piridil, 3-piridil, 4-piridil, 2-pirimidinil, 4-pirimidinil, 5-pirimidinil, svaki nesupstituiran ili supstituiran članu ugljikovog prstena sa jednom ili dvije Ra funkcionalne grupe; gdje je svaka Ra funkcionalna grupa nezavisno izabrana iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4alkil, -CO2H, -COC1-4alkil, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc oba nezavisno -H ili -C1-4alkil; i Ar2 je: (a) nesupstituirane 1-naftil; ili fenantrenil, pirenil, fluorenil, 2-naftul, ili N-Rd-9H-karbazolil funkcionalne grupe, gdje je Rd izabrano iz grupe koja se sastoji od -H, -C1-4alkil, i fenil, svaka spomenuta funkcionalna grupa nesupstituirana ili supstituirana sa jednim, dva, ili tri Re supstituenta, gdje je svaki Re supstituent nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4alkil, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (b) fenil fuzioniran na dva susjedna atoma ugljikovog prstena za grupu izabranu iz grupe koja se sastoji od -(CH2)3-5- koja ima 0 ili 1 duple veze, -OCH2CH2O-, i -OCF2O- čime formira fuzioniranu prstenastu strukturu; ili fenil supstituiran na susjednim atomima ugljikovog prstena sa -OCH2O- čime formira 4-benzo[1,3]dioksolil; svaka fenil funkcionalna grupa dalje nesupstituirana ili supstituirana sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (c) Ar6, gdje Ar6 je šestočlani monociklički heteroaril koji ima ugljik kao točku vezivanja, sa jednim ili dva heteroatoma dušika, nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (d) devetočlani ili desetočlani fuzionirani biciklični heteroaril koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa atomom ugljika kao točkom prstenastog vezanja, i koji opcijski ima do četiri dodatna atoma ugljikovog prstena zamijenjena sa dušikom, spomenutim fuzioniranim bicikličnim heteroarilom koji ima ne više od pet heteroatoma, i nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano; (e) fenil supstituiran na trećoj ili četvrtoj poziciji sa Rg, i opcijski dalje supstituiran sa jednim, dva, ili tri Rh supstituenta, gdje je svaki Rg nezavisno izabran iz grupe koja se sastoji od -C2-8alkil, -C2-8alkenil, -OC3-8cikloalkil, -OC3-8heterocikloalkil, i -O-C2-10alkil opcijski supstituiran sa –NRiRj, gdje su Ri i Rj oba nezavisno -H ili -C1-8alkil, ili Ri i Rj uzeti zajedno sa vezujućim atomom dušikovog prstena čime se formira petočlani, šestočlani, ili sedmočlani heterocikloalkil prsten koji opcijski ima jedan dodatni atom ugljikovog prstena zamijenjen sa O, S, >NH, ili >NC1-4alkil; i svaki Rh supstituent je nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (f) fenil supstituiran na trećoj i četvrtoj poziciji sa -1-Ar3, gdje: o L je veznik izabran iz grupe koja se sastoji od -(CH2)1-3-, -CH=CH-, -O-, -OCH2-, -CH2O-, -NH-, >NC1-4alkil, >S(=O)0-2, -OSO2-, -CΞC-, -C(=O)-, i kovalentna veza; i o Ar3 je funkcionalna grupa izabrana iz grupe koja se sastoji od: (1) fenil, naftil, i fenantrenil, (2) Ar6’, gdje Ar6’ je šestočlani monociklički heteroaril koji ima ugljik kao točku vezanja, koji ima jedan ili dva heteroatoma dušika, (3) Ar5’, gdje Ar5’ je petočlani monociklički heteroaril koji ima ugljik kao točku vezanja, sa jednim heteroatomom izabranim iz grupe koja se sastoji od O, S, >NH, i >NRf, gdje Rf je -C1-8alkil ili -C0-3fenalkil, i ima nula, jedan, dva, ili tri dodatna heteroatoma dušika, i (4) devetočlani ili desetočlani fuzionirani biciklični heteroaril, koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa ugljikom kao točkom prsten vezanja, i koji opcijski ima do četiri dodatna atoma ugljikovog prstena zamijenjena sa dušikom, spomenutim fuzioniranim bicikličnim heteroarilom koji ima ne više od 5 heteroatoma; gdje je svaka od funkcionalnih grupa (1) do (4) opcijski de-supstituirana na susjednim ugljicima sa -OC1-4alkilenO-, -(CH2)2-3NH-, -(CH2)1-2NH(CH2)-, -(CH2)2-3N(C1-4alk il)-, ili -(CH2)1-2N(C1-4alkil)(CH2)- čime formira fuzioniranu prstenastu strukturu, i opcijski je dalje supstituirana sa jednim, dva, ili tri Rk supstituenta, gdje je svaki Rk supstituent nezavisno izabran iz grupe koja se sastoji od -C1-4alkila, -C2-4alkenila, -OH, -OC1-4alkila, halo, -CF3, -OCF3, -SCF3, -SH, -S(O)0-2C1-4alkila, -OSO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; (g) 2-hidroksifenil ili 2-metoksifenil, nesupstituiran ili supstituiran sa jednim, dva, ili tri RI supstituenta, gdje je svaki RI supstituent nezavisno izabran iz grupe koja se sastoji od -CH3, 6-C2-4alkila, 6-C2-4alkenila, -OH, -OCH3, 6-OC2-6alkila, halo, -CF3, -OCF3, -SCF3, -SH, -SC1-4alkila, -SO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN,gdje su Rb i Rc kao što je prethodno definirano; (h) 4-halofenil, nesupstituiran ili supstituiran sa jednim, dva, ili tri Rm supstituenta, gdje je svaki Rm supstituent nezavisno izabran iz grupe koja se sastoji od -CH3, 2-C2-4alkila, 2-C2-4alkenila, 3-hidroksi, 4-hidroksi, -OCH3, 2-OC2-6alkila, halo, -CF3, -OCF3, -SCF3, -SH, -SC1-4alkila, -SO2C1-4alkila, -CO2C1-4alkila, -CO2H, -COC1-4alkila, -N(Rb)Rc, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NO2, i -CN, gdje su Rb i Rc kao što je prethodno definirano; ili (i) 2-bromofenil, 3-metilfenil, 3-metoksifenil, 4-metoksifenil, ili 3,4-dimetoksifenil; i farmaceutsko prihvatljivih soli istih; i (b) farmaceutsko prihvatljivog ekscipijenta
32. Farmaceutski pripravak prema patentnom zahtjevu 31, naznačen time da je spomenuti agens izabran iz grupe koja se sastoji od: 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina piridin-3-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina piridin-2-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina piridin-4-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina pirimidin-2-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1-karboksilna kiselina piridin-3-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1-karboksilna kiselina piridin-4-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1-karboksilna kiselina pirimidin-2-ilamida; 4-benzo[1,3]dioksol-5-ilmetil-piperazin-1-karboksilna kiselina piridin-2-ilamida; 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1-karboksilna kiselina piridin-3-ilamida; 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1-karboksilna kiselina piridin-4-ilamida; 4-hinolin-3-ilmetil-piperazin-1-karboksilna kiselina pirimidin-4-ilamida; 4-(2,2-difluoro-benzo[1,3]dioksol-5-ilmetil)-piperazin-1-karboksilna kiselina pirimidin-4-ilamida; 4-(3,4-dibromo-benzil)-piperazin-1-karboksilna kiselina pirimidin-4-ilamida; i farmaceutski prihvatljive soli istih.
33. Farmaceutski pripravak prema patentnom zahtjevu 31, naznačen time da dalje sadrži: analgetik izabran iz grupe koja se sastoji od opioida i nesteroidnih anti-inflamatornih lekova
34. Farmaceutski pripravak prema patentnom zahtjevu 31, naznačen time da dalje sadrži: dodatni aktivni sastojak izabran iz grupe koja se sastoji od aspirina, acetaminofena, opioidia, ibuprofena, naproksena, COX-2 inhibitora, gabapentina, pregabalina, i tramadola.
HRP20150765TT 2004-12-30 2015-07-13 Amid derivati piperidin- i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za lijeäśenje tjeskobe, boli i drugih stanja HRP20150765T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64086904P 2004-12-30 2004-12-30
EP20050855824 EP1836179B1 (en) 2004-12-30 2005-12-29 Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
PCT/US2005/047329 WO2006074025A1 (en) 2004-12-30 2005-12-29 Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase

Publications (1)

Publication Number Publication Date
HRP20150765T1 true HRP20150765T1 (hr) 2015-10-09

Family

ID=36153917

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20150765TT HRP20150765T1 (hr) 2004-12-30 2015-07-13 Amid derivati piperidin- i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za lijeäśenje tjeskobe, boli i drugih stanja
HRP20171294TT HRP20171294T1 (hr) 2004-12-30 2017-08-28 Derivati fenilamid 4-(benzil)-piperazin-1-karboksilne kiseline i slični spojevi kao modulatori amidazne hidrolaze masne kiseline (faah) za liječenje tjeskobe, boli i drugih stanja

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20171294TT HRP20171294T1 (hr) 2004-12-30 2017-08-28 Derivati fenilamid 4-(benzil)-piperazin-1-karboksilne kiseline i slični spojevi kao modulatori amidazne hidrolaze masne kiseline (faah) za liječenje tjeskobe, boli i drugih stanja

Country Status (34)

Country Link
US (3) US7598249B2 (hr)
EP (2) EP1836179B1 (hr)
JP (2) JP5507810B2 (hr)
KR (1) KR101287955B1 (hr)
CN (1) CN101146786B (hr)
AR (1) AR055831A1 (hr)
AU (1) AU2005322920B2 (hr)
BR (1) BRPI0519343A2 (hr)
CA (1) CA2596393C (hr)
CR (1) CR9277A (hr)
CY (1) CY1119428T1 (hr)
DK (2) DK2937341T3 (hr)
EA (1) EA012589B1 (hr)
ES (2) ES2542021T3 (hr)
HK (2) HK1107641A1 (hr)
HR (2) HRP20150765T1 (hr)
HU (2) HUE025313T2 (hr)
IL (1) IL184295A (hr)
LT (1) LT2937341T (hr)
ME (2) ME02929B (hr)
MX (1) MX2007008134A (hr)
NI (1) NI200700166A (hr)
NO (1) NO338957B1 (hr)
NZ (1) NZ590148A (hr)
PE (1) PE20061114A1 (hr)
PL (2) PL1836179T3 (hr)
PT (2) PT1836179E (hr)
RS (2) RS54136B1 (hr)
SI (2) SI1836179T1 (hr)
TW (1) TWI382977B (hr)
UA (1) UA89514C2 (hr)
UY (1) UY29321A1 (hr)
WO (1) WO2006074025A1 (hr)
ZA (1) ZA200706253B (hr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
ES2542021T3 (es) * 2004-12-30 2015-07-29 Janssen Pharmaceutica Nv Derivados amida del ácido piperidina- y piperazina-1-carboxílico y compuestos relacionados como moduladores de la amida hidrolasa de ácidos grasos (faah) para el tratamiento de la ansiedad, el dolor y otras afecciones
GB0503056D0 (en) * 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
PE20070099A1 (es) * 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
EP1923388A4 (en) * 2005-08-12 2011-03-09 Takeda Pharmaceutical BRAIN / NERVE CELL PROTECTION AND THERAPEUTIC FOR SLEEP DISORDERS
WO2007086584A1 (ja) * 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規ＦａｂＫおよびＦａｂＩ／Ｋ阻害剤
ITRM20060090A1 (it) * 2006-02-22 2007-08-23 Sigma Tau Ind Farmaceuti Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita
JP2009538358A (ja) * 2006-05-26 2009-11-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
WO2008023720A1 (fr) 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
PT2076508E (pt) 2006-10-18 2011-03-07 Pfizer Prod Inc Compostos de ureia de éter biarílico
EP2164493A2 (en) * 2007-05-25 2010-03-24 Janssen Pharmaceutica, N.V. Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
CA2714743C (en) * 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
EP2276736A1 (en) * 2008-04-17 2011-01-26 Pfizer Inc. 4- [3- (aryloxy) benzyliden]-3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
CA2719789A1 (en) * 2008-04-17 2009-10-22 Pfizer Inc. 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors
US20110144159A1 (en) * 2008-04-17 2011-06-16 Pfizer Inc Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
WO2009127949A1 (en) * 2008-04-17 2009-10-22 Pfizer Inc. 4- [3- (aryloxy) benzylidene] -3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
EP2276738A1 (en) * 2008-04-17 2011-01-26 Pfizer Inc. Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
US8080566B1 (en) 2008-06-11 2011-12-20 Kalypsys, Inc Carbazole inhibitors of histamine receptors for the treatment of disease
US20100113465A1 (en) * 2008-10-30 2010-05-06 Pfizer Inc. 7-azaspiro[3.5]nonane-7-carboxamide compounds
JP2012509309A (ja) * 2008-11-21 2012-04-19 ファイザー・インク Ｆａａｈ阻害剤としての１−オキサ−８−アザスピロ［４．５］デカン−８−カルボキサミド化合物
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
CN105399731A (zh) * 2008-12-24 2016-03-16 比亚尔-珀特拉和Ca股份公司 药物化合物
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
WO2010141809A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
US20120225097A1 (en) 2009-11-12 2012-09-06 Hawryluk Natalie A Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
WO2011078369A1 (ja) 2009-12-25 2011-06-30 持田製薬株式会社 新規アリールウレア誘導体
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
BR112012018913A2 (pt) * 2010-01-28 2017-06-20 Merck Sharp & Dohme "composição farmacêutica, e, uso da composição"
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
UA108233C2 (uk) * 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
US9682953B2 (en) 2011-09-23 2017-06-20 Advinus Therapeutics Limited Amide compounds, compositions and applications thereof
EP3698782A1 (en) 2012-01-06 2020-08-26 Lundbeck La Jolla Research Center, Inc. Carbamate compounds for use in therapy
WO2013170072A2 (en) * 2012-05-09 2013-11-14 Neurop, Inc. Compounds for the treatment of neurological disorders
CN104582794A (zh) * 2012-08-31 2015-04-29 诺瓦药品公司 用于治疗病毒性疾病的杂环基氨甲酰
EP2956441A4 (en) * 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
WO2014179144A1 (en) * 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
ES2640800T3 (es) * 2013-07-24 2017-11-06 BIAL - PORTELA & Cª, S.A. Imidazolcarboxamidas y su uso como inhibidores de la FAAH
JP2017529401A (ja) * 2014-09-26 2017-10-05 チャーンジョウ インシュヨン ファーマシューティカル カンパニー，リミティド Ｎｓ４ｂ阻害剤としてのベンゾフラン類似体
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
JP2018513119A (ja) * 2015-03-18 2018-05-24 アビデ セラピューティクス，インク． ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
BR112018076258A2 (pt) * 2016-06-30 2019-03-26 Basilea Pharm Int Ag inibidores mitocondriais para o tratamento de distúrbios de proliferação
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
TW201927302A (zh) * 2017-10-12 2019-07-16 瑞士商巴塞利亞藥業國際股份有限公司 用於治療增殖障礙之線粒體抑制劑
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
EP3737361A4 (en) 2018-01-11 2021-08-25 Centaurus Therapeutics DIHYDROCERAMIDE DESATURASE INHIBITORS FOR THE TREATMENT OF DISEASE
AR115092A1 (es) 2018-05-15 2020-11-25 Abide Therapeutics Inc Inhibidores de magl
US11897865B2 (en) 2018-05-15 2024-02-13 The Scripps Research Institute ABHD12 inhibitors and methods of making and using same
CN110878070B (zh) * 2018-09-06 2021-08-31 中国科学院化学研究所 一种制备不对称脲类化合物的方法
EP3968994B1 (en) * 2019-05-14 2023-12-27 H. Lundbeck A/S Abhd12 inhibitors and methods of making and using same
JP2023523219A (ja) 2020-04-21 2023-06-02 ハー・ルンドベック・アクチエゼルスカベット モノアシルグリセロールリパーゼ阻害剤の合成
EP4163273A1 (en) 2021-10-07 2023-04-12 Universita' Degli Studi Di Pavia Substituted vinyl piperazine-piperidine urea derivatives as anticancer agents
CN114605385B (zh) * 2022-03-25 2023-09-08 河南大学 吲哚哌啶脲类trpv1拮抗/faah抑制双靶点药物及制备方法和应用
WO2024059333A1 (en) * 2022-09-16 2024-03-21 Ohio State Innovation Foundation Compounds for treating infections with parasitic protozoa

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1292410A (en) 1970-05-13 1972-10-11 Yoshitomi Pharmaceutical Thienobenzothiazepine derivatives
JPS5347725Y2 (hr) 1971-06-18 1978-11-15
JPS5515456A (en) * 1978-07-19 1980-02-02 Morishita Seiyaku Kk 2-substituted-piperazinomethyl-1,4-benzodioxane
NZ223847A (en) 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions
WO1993000342A1 (en) 1991-06-21 1993-01-07 Boehringer Mannheim Italia S.P.A. 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
JPH0810160A (ja) 1994-06-28 1996-01-16 Tokyo Gas Co Ltd 食品スチーマー
US5612380A (en) 1994-09-27 1997-03-18 The Scripps Research Institute Method for sleep induction
CZ288002B6 (cs) * 1995-01-11 2001-03-14 Samjin Pharmaceutical Co., Ltd. Piperazinové deriváty a farmaceutický prostředek s protinádorovou aktivitou je obsahující
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
NZ332116A (en) 1996-05-03 2000-06-23 Warner Lambert Co Rapid purification of synthetic intermediates and products by polymer supported quench reagents
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
EP0968200A1 (en) 1997-02-24 2000-01-05 ZymoGenetics, Inc. Calcitonin mimetics
JPH11139969A (ja) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
WO1999024421A1 (en) 1997-11-07 1999-05-20 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
DE69833791D1 (de) 1997-11-24 2006-05-04 Scripps Research Inst Hemmer der "gap junction communication"
US6268367B1 (en) * 1998-02-23 2001-07-31 Zymogenetics, Inc. Piperazine derivatives for treating bone deficit conditions
NZ525108A (en) 1998-03-31 2005-02-25 Acadia Pharm Inc Compounds with activity on muscarinic receptors
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
US6100279A (en) * 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
WO2001036386A1 (fr) * 1999-11-17 2001-05-25 Sumitomo Pharmaceuticals Co., Ltd. Traitement du diabete contenant un derive de dipiperazine
US6462054B1 (en) 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
BR0112631A (pt) 2000-07-20 2003-09-23 Neurogen Corp Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
DE10047760A1 (de) 2000-09-27 2002-04-11 Henkel Kgaa Zahnreinigungsmittel
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
GB0031088D0 (en) * 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1389107A4 (en) 2001-04-27 2005-10-12 Bristol Myers Squibb Co BISARYLIMIDAZOLYL-FATTY ACID AMIDE-HYDROLASE INHIBITORS
SK288015B6 (sk) 2001-06-11 2012-11-05 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
AU2002363236A1 (en) * 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
AU2002351200A1 (en) 2001-12-03 2003-06-17 Gpc Biotech, Inc. Compositions and methods for inhibiting prenyltransferases
US6727247B2 (en) 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
AU2003210824A1 (en) 2002-02-08 2003-09-02 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
US7662971B2 (en) 2002-10-08 2010-02-16 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
FR2850377B1 (fr) 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1604981A4 (en) 2003-03-14 2008-12-24 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
US20040191155A1 (en) 2003-03-25 2004-09-30 Mahler Barry Asher Thermal process for reducing the concentration of dinitrogen difluoride and dinitrogen tetrafluoride in nitrogen trifluoride
FR2854633B1 (fr) 2003-05-07 2005-06-24 Sanofi Synthelabo Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
DE602004013772D1 (de) 2003-06-10 2008-06-26 Janssen Pharmaceutica Nv Kombination von opioiden und einem piperazin-derivat für die behandlung von schmerzen
US7262020B2 (en) 2003-07-03 2007-08-28 The Regents Of The University Of California Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
US7725550B2 (en) 2004-12-17 2010-05-25 Nhn Corporation System and method for filtering message
ES2542021T3 (es) 2004-12-30 2015-07-29 Janssen Pharmaceutica Nv Derivados amida del ácido piperidina- y piperazina-1-carboxílico y compuestos relacionados como moduladores de la amida hidrolasa de ácidos grasos (faah) para el tratamiento de la ansiedad, el dolor y otras afecciones
US7331398B2 (en) * 2005-06-14 2008-02-19 Schlumberger Technology Corporation Multi-drop flow control valve system
PE20070099A1 (es) 2005-06-30 2007-02-06 Janssen Pharmaceutica Nv N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso
ITRM20060090A1 (it) 2006-02-22 2007-08-23 Sigma Tau Ind Farmaceuti Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita
DE602007009221D1 (de) 2006-05-18 2010-10-28 Hoffmann La Roche Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor
WO2008024139A2 (en) 2006-08-18 2008-02-28 N.V. Organon Inhibitors of fatty acid amide hydrolase
WO2008023720A1 (fr) 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
PT2076508E (pt) 2006-10-18 2011-03-07 Pfizer Prod Inc Compostos de ureia de éter biarílico
EP2164493A2 (en) 2007-05-25 2010-03-24 Janssen Pharmaceutica, N.V. Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US20090163508A1 (en) 2007-10-10 2009-06-25 Takeda Pharmaceutical Company Limited Amide compound
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en) 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase

Also Published As

Publication number Publication date
EP1836179A1 (en) 2007-09-26
US20130331396A1 (en) 2013-12-12
NI200700166A (es) 2008-02-04
ES2639621T3 (es) 2017-10-27
US20100004261A1 (en) 2010-01-07
BRPI0519343A2 (pt) 2009-01-20
KR101287955B1 (ko) 2013-07-23
ME02929B (me) 2018-04-20
US9169224B2 (en) 2015-10-27
CY1119428T1 (el) 2018-03-07
DK2937341T3 (en) 2017-09-11
PT2937341T (pt) 2017-09-01
RS56194B1 (sr) 2017-11-30
NO20073923L (no) 2007-09-05
UA89514C2 (uk) 2010-02-10
US20060173184A1 (en) 2006-08-03
PE20061114A1 (es) 2006-11-10
HK1118282A1 (en) 2009-02-06
US7598249B2 (en) 2009-10-06
ES2542021T3 (es) 2015-07-29
ME02222B (me) 2016-02-20
HK1107641A1 (en) 2008-04-11
HUE033441T2 (en) 2017-11-28
EA012589B1 (ru) 2009-10-30
TW200635912A (en) 2006-10-16
MX2007008134A (es) 2008-01-16
ZA200706253B (en) 2009-01-28
WO2006074025A1 (en) 2006-07-13
AU2005322920B2 (en) 2012-06-21
IL184295A (en) 2015-10-29
SI1836179T1 (sl) 2015-07-31
CA2596393C (en) 2014-09-23
PT1836179E (pt) 2015-09-11
KR20070094635A (ko) 2007-09-20
CN101146786A (zh) 2008-03-19
CN101146786B (zh) 2013-03-27
US8530476B2 (en) 2013-09-10
WO2006074025B1 (en) 2006-08-31
NO338957B1 (no) 2016-11-07
JP2012236848A (ja) 2012-12-06
JP2008526755A (ja) 2008-07-24
AU2005322920A1 (en) 2006-07-13
SI2937341T1 (sl) 2017-10-30
JP5507810B2 (ja) 2014-05-28
EP2937341B1 (en) 2017-07-05
AR055831A1 (es) 2007-09-12
DK1836179T3 (en) 2015-05-26
LT2937341T (lt) 2017-09-11
HRP20171294T1 (hr) 2017-10-20
NZ590148A (en) 2012-04-27
EP1836179B1 (en) 2015-05-06
TWI382977B (zh) 2013-01-21
CR9277A (es) 2008-09-09
PL1836179T3 (pl) 2015-10-30
PL2937341T3 (pl) 2017-11-30
EP2937341A1 (en) 2015-10-28
RS54136B1 (en) 2015-12-31
EA200701416A1 (ru) 2007-12-28
HUE025313T2 (en) 2016-02-29
IL184295A0 (en) 2007-10-31
UY29321A1 (es) 2006-03-31
CA2596393A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
HRP20150765T1 (hr) Amid derivati piperidin- i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za lijeäśenje tjeskobe, boli i drugih stanja
USRE42477E1 (en) Carboxylic acid derivatives, their preparation and use
AU2003206833B2 (en) Novel pyridin- and pyrimidin-derivatives
JPS6084282A (ja) １−ヘテロアリ−ル−４−〔（２．５−ピロリジンジオン−１−イル）アルキル〕ピペラジン誘導体
JPH07107051B2 (ja) Ｈｉｖ逆転写酵素の阻害物質
JP2004531531A5 (hr)
EP1254119A1 (en) Pyrimidine derivatives as selective inhibitors of cox-2
US20130183388A1 (en) Novel IDO Inhibitors and Methods of Use Thereof
JP2010006817A (ja) 炎症性障害を治療する化合物
JP2008517983A5 (hr)
CA2556946A1 (en) Pyrrolopyrimidine derivatives
JPH09505050A (ja) ピリミジン−チオアルキルおよびアルキルエーテル化合物
KR101446680B1 (ko) ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
JP2003514898A (ja) Ｃｏｘ−２の選択的阻害剤としてのピリミジン誘導体
CA2577879A1 (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i.epsilon.
JP2014528450A (ja) 肝細胞癌を含む癌の阻害剤、および肝炎ウイルス複製の阻害剤としての置換アミノチアゾール
JPH09301958A (ja) 新規ピリミジン化合物及び抗ロタウイルス剤
JP2008521855A (ja) 新規ピリドチエノピリミジン誘導体
JP2000508670A (ja) ピペリジン化合物およびピロリジン化合物
JP2013507329A (ja) 脈管系および中枢神経系に作用する三環系化合物および四環系化合物
CN1922147A (zh) 作为类胰岛素生长因子第1类受体抑制剂的新颖杂环化合物
SK14152002A3 (sk) Spôsob prípravy citalopramu a antidepresívny farmaceutický prostriedok s obsahom citalopramu
US6525067B1 (en) Substituted heterocyclic derivatives
JP6120311B2 (ja) ポリフェノール化合物
HRP980126A2 (en) Novel carboxilic acid derivatives, their preparation and use in treating cancer